Figure 4. Stratifying by stages patient’s survival in groups with high or low frequency of CD57+CD56^dim NK cells in tumor-infiltrated lymph nodes.

(a) CD57+CD56^dim/CD57+CD56^bright ratio was calculated as a proportion of total NK cell frequency in the melanoma infiltrated lymph nodes (TILN) of each metastastic melanoma patient. (b) Kaplan-Meier survival curves in 7 patients with CD57+CD56^dim/CD57+CD56^bright ratio≥6 (continuous line), 6 patients with CD57+CD56^dim/CD57+CD56^bright ratio<6 stage III (dashed line) and with 6 patients CD57+CD56^dim/CD57+CD56^bright ratio<6 in stage IV (dotted line). The curves were compared with Log Rank Test (P=0.004) and a test for trend (P=0.00068).